Suppr超能文献

对于接受根治性肾输尿管切除术治疗且已度过五年无膀胱肿瘤期的上尿路尿路上皮癌患者,是否应进行随访膀胱镜检查?

Should follow-up cystoscopy be performed in upper-tract urothelial carcinoma patients managed with radical nephroureterectomy after a five-year bladder tumor-free period?

作者信息

Wang Guoli, Guan Bao, Du Yicong, Tang Qi, Xu Chunru, Yang Qian, Ren Hanzhen, Zhang Huifeng, Cao Chao, Luo Kaishun, Li Zhihua, Zhou Liqun, Zhang Kai, Li Xuesong

机构信息

Department of Urology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, , Beijing, 100034, China.

Institute of Urology, Peking University, Beijing, China.

出版信息

Discov Oncol. 2025 Jun 19;16(1):1155. doi: 10.1007/s12672-025-02698-7.

Abstract

There is a lack of consensus regarding the follow-up schedule for patients with upper-tract urothelial carcinoma (UTUC) who remain bladder recurrence-free for 5 years after radical nephroureterectomy (RNU). In this study, we aimed to identify the risk factors for late recurrence in UTUC patients who remained bladder recurrence-free for at least 5 years post-RNU. Data from a large single-center Chinese institution were retrospectively analyzed. A total of 939 patients who remained recurrence-free for at least 5 years post-RNU were included in this study. To determine the risk factors for late bladder recurrence after RNU, we applied univariate and multivariate analyses using the Fine-Gray model, considering death as a competing risk. During a median follow-up of 97 months, 45 (4.8%) developed bladder recurrence, 207 (22%) died, and 61 (6.5%) succumbed to UTUC. The cumulative risk of bladder recurrence was 6.3% at 10 years and 13.9% at 15 years. The peak incidence of late bladder recurrence was observed between 70 and 90 months post-RNU. Univariate analysis revealed that Chronic Kidney Disease (CKD) stage 5 was significantly associated with late bladder recurrence.Multivariate analysis revealed that CKD stage 5 and tumor diameter less than 3 cm were independent risk factors for late bladder recurrence. These findings indicate that late bladder recurrence is uncommon and patients with CKD stage 5 or tumor diameter less than 3 cm are at a higher risk of late bladder recurrence, warranting prolonged cystoscopic surveillance for for 5 to 10 years post-RNU.

摘要

对于接受根治性肾输尿管切除术(RNU)后膀胱无复发达5年的上尿路尿路上皮癌(UTUC)患者的随访方案,目前尚无共识。在本研究中,我们旨在确定RNU术后膀胱无复发至少5年的UTUC患者发生晚期复发的危险因素。我们对来自中国一家大型单中心机构的数据进行了回顾性分析。本研究共纳入939例RNU术后至少5年无复发的患者。为了确定RNU术后晚期膀胱复发的危险因素,我们使用Fine-Gray模型进行单因素和多因素分析,将死亡视为竞争风险。在中位随访97个月期间,45例(4.8%)发生膀胱复发,207例(22%)死亡,61例(6.5%)死于UTUC。膀胱复发的累积风险在10年时为6.3%,在15年时为13.9%。晚期膀胱复发的高峰发病率出现在RNU术后70至90个月之间。单因素分析显示,慢性肾脏病(CKD)5期与晚期膀胱复发显著相关。多因素分析显示,CKD 5期和肿瘤直径小于3 cm是晚期膀胱复发的独立危险因素。这些发现表明,晚期膀胱复发并不常见,CKD 5期或肿瘤直径小于3 cm的患者发生晚期膀胱复发的风险较高,因此在RNU术后需要进行5至10年的长期膀胱镜监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e63/12179018/0fc2e045bba7/12672_2025_2698_Fig1_HTML.jpg

相似文献

3
Aural toilet (ear cleaning) for chronic suppurative otitis media.
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013057. doi: 10.1002/14651858.CD013057.pub3.
4
Interventions for central serous chorioretinopathy: a network meta-analysis.
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
5
Prognostic factors for return to work in breast cancer survivors.
Cochrane Database Syst Rev. 2025 May 7;5(5):CD015124. doi: 10.1002/14651858.CD015124.pub2.
6
Topical fluoride as a cause of dental fluorosis in children.
Cochrane Database Syst Rev. 2024 Jun 20;6(6):CD007693. doi: 10.1002/14651858.CD007693.pub3.
7
Electronic cigarettes for smoking cessation.
Cochrane Database Syst Rev. 2024 Jan 8;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub8.
9
Surgical approaches for inserting hemiarthroplasty of the hip in people with hip fractures.
Cochrane Database Syst Rev. 2025 Jun 13;6(6):CD016031. doi: 10.1002/14651858.CD016031.
10
Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.
Cochrane Database Syst Rev. 2023 Sep 12;9(9):CD015226. doi: 10.1002/14651858.CD015226.pub2.

本文引用的文献

1
Prevalence and oncologic impact of chronic kidney disease for upper tract urothelial carcinoma in endemic area.
J Formos Med Assoc. 2024 Jul;123(7):758-763. doi: 10.1016/j.jfma.2023.11.011. Epub 2023 Dec 2.
2
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
J Urol. 2023 Jun;209(6):1071-1081. doi: 10.1097/JU.0000000000003480. Epub 2023 Apr 25.
3
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24.
5
Prognostic value of renal function for upper tract urothelial carcinoma who underwent radical nephroureterectomy: Sex differences.
J Formos Med Assoc. 2022 Nov;121(11):2182-2190. doi: 10.1016/j.jfma.2022.03.012. Epub 2022 Mar 31.
6
Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.
Nat Rev Urol. 2022 May;19(5):280-294. doi: 10.1038/s41585-022-00578-1. Epub 2022 Mar 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验